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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016cyclosporine was successful in 75% of patients in treating frequent
relapses. Mean time to achieve remission was 3.2 months. Overall
Tacrolimus was successful in 77% of patients in treating frequent
relapses. Mean time to achieve remission was 2.1 months. Out of 15
patients with steroid resistant nephrotic syndrome, 3 patients
treated with cyclosporine, 1 achieved partial remission and still
continued on CSA where as 2 patients did not respond. Time to
achieve remission was 5 months. 2 patients resistant to cyclosporine
and 12 steroid resistant patients were treated with tacrolimus (total
14 patients). 11 of 14 (79%) patients achieved complete remission
and 2(14%) achieved partial remission. Mean time to achieve
remission was 2.5 months. In SRNS patients, tacrolimus was more
effective than cyclosporine and was also effective in 1 pt resistant
to CSA.
Conclusions: In frequent relapsing nephrotic syndrome patients,
both cyclosporine and tacrolimus has comparable efﬁcacy and no
signiﬁcant difference. Overall success rate (CR, PR and infrequent
relapses) was 75% and 77% respectively. In steroid resistant
nephrotic syndrome patients, tacrolimus was more effective than
cyclosporine and also effective in CSA resistant patients. Combined
remission rate (CR & PR) of 93% with tacrolimus as compare to only
33% with cyclosporine was achieved in SRNS. Late steroid resis-
tance is associated with better response to CNI therapy as compared
to primary CNI resistance.
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Introduction: Current guidelines suggest treatment with cortico-
steroids (CS) in IgA nephropathy (IgAN) with persistent proteinuria
>1 g/day despite 3–6 months of supportive care and eGFR
>50 ml/min/1.73m2. Whether the beneﬁts of this treatment extend
to patients with an eGFR<50 ml/min/1.73m2 is unclear. We
retrospectively studied the effect of steroids on disease progression
and proteinuria in IgA N patients with eGFR < 50ml/min/1.73m2
compared to those with >50ml/min/1.73m2.
Methods: A cohort of biopsy proven primary IgA N diagnosed
between March 2010 and February 2015 who received oral corti-
costeroids and followed-up for a minimum of six months were
included. They were categorized into two groups as per eGFR.
(Group 1 – eGFR>50 ml/min/1.73m2, Group 2 – eGFR < 50ml/min/
1.73m2). Baseline characteristics were compared between the
groups. The eGFR and urine protein creatinine ratio (UPCR) were
followed up at entry time, 6 months, 12 months and at the end of
follow-up. Outcomes studied were change in eGFR, proteinuria and
progression to end stage renal disease (ESRD). Statistical analysis
was done using SPSS version 16.
Results: Out of 44 patients, 23(52%) had eGFR< 50 ml/min/1.73m2
(Group1) and 21(48%) had eGFR >50ml/min/1.73m2 (Group 2). The
baseline clinical, histopathological, and treatment characteristics of
both the groups are shown in table 1. At the end of follow-up,Kidney International Reports (2016) 1, S1–S22similar reduction of proteinuria (UPCR) (p-0.62) was seen in both
the groups. But there was signiﬁcant difference in change in me-
dian eGFR/month (p-0.004) (Table 2). Patients in Group 2 had a
median fall in eGFR of -0.46 ml/min/1.73m2 / month, whereas
Group 1 had an increase in median eGFR by +0.38ml/min/1.73m2/
month (Table 2). One in each group has reached CKD stage
5(p-0.73). Limitations in our study were retrospective in nature,
small cohort and short duration of follow-up.
Table 2. Outcomes at the end of follow-up between groups
Group 1(N[23) (%) Group 2-(N-21)(%)Characteristic
(eGFR < 50
ml/min/1.73m2)
(eGFR > 50
ml/min/1.73m2)
‘p’
valueInitial eGFR# 25.13(19.33,39.51) 82.7(76,115.85)eGFR at end of follow-
up#20.94(9.36,37.12) 94.43(77.48,129.91)Change in eGFR/
month#-0.46(-0.1,-1.08) +0.38(+1.06,0.00) 0.004Initial UPCR# 2.6(1.8,3.3) 2(1.7,3.1)UPCR at the end of
follow-up#1.0(0.6,2.0) 1.0(0.6,2.0)Change in UPCR# 1.4(0.3,2.0) 1.5(0.55,2.75) 0.61Patients reaching ESRD 1(4.3) 1(4.7) 0.73#- Median with interquartile range, *- Mean with standard deviation, estimated
glomerular ﬁltration rate (eGFR), Urine protein-to- creatinine ratio(UPCR)
Conclusions: Addition of corticosteroids to conservative treatment
in IgA N patients with initial eGFR<50 ml/min/1.73m2 seems to
reduce proteinuria but not beneﬁcial in preventing progression of
disease as compared to patients with higher eGFR (>50ml/ min/
1.73m2). However we need large prospective randomized control
trials with long term follow-up to conﬁrm role of steroids in this
subset of IgA N.
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